How the concept of biochemical response influenced the management of primary biliary cholangitis over time.
暂无分享,去创建一个
J. Drenth | K. V. van Erpecum | K. Boonstra | B. Witteman | B. Hansen | G. Erkelens | M. Verhagen | J. Kuyvenhoven | G. Koek | F. ter Borg | A. C. Poen | A. Poen | E. Witteman | J. Brouwer | J. Vrolijk | C. V. van Nieuwkerk | M. Leeman | B. van der Spek | C. Ponsioen | W. Lammers | S. V. van Tuyl | T. J. van Ditzhuijsen | F. Wolfhagen | F. Ter Borg | T. van Ditzhuijsen
[1] K. Lindor,et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.
[2] Andrew K Burroughs,et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study , 2015, Gut.
[3] A. Burroughs,et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.
[4] C. Ponsioen,et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population‐based study , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[5] J. Neuberger,et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. , 2014, Journal of hepatology.
[6] D. Jones,et al. P399 PBC MANAGEMENT AMONG CLINICIANS: GAPS IN CLINICAL COMPETENCE AND PRACTICE PERFORMANCE – SURVEY FINDINGS , 2014 .
[7] S. Lens,et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[8] T. Miyazaki,et al. AUTOIMMUNE , CHOLESTATIC , AND BILIARY DISEASE Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid , 2013 .
[9] G. Alexander,et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. , 2013, Gastroenterology.
[10] K. Lindor,et al. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[11] O. Chazouilleres,et al. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. , 2011, Journal of hepatology.
[12] K. Lindor,et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid , 2011, Alimentary pharmacology & therapeutics.
[13] T. Arenovich,et al. Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis , 2010, The American Journal of Gastroenterology.
[14] G. Gores,et al. American association for the study of liver diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis , 2010, Hepatology.
[15] Y. Chrétien,et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. , 2010, Gastroenterologie clinique et biologique.
[16] K. V. van Erpecum,et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. , 2009, Gastroenterology.
[17] M. Kaplan,et al. Primary biliary cirrhosis , 1998, Hepatology.
[18] F. Lammert,et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. , 2009, Journal of hepatology.
[19] Y. Chrétien,et al. Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.
[20] B. Hansen,et al. Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients , 2006, The American Journal of Gastroenterology.
[21] J. Rodés,et al. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. , 2006, Gastroenterology.
[22] M. Färkkilä,et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial , 2005, Hepatology.
[23] M. Abe,et al. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis , 2005, Journal of Gastroenterology.
[24] T. Masaki,et al. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study , 2000, American Journal of Gastroenterology.
[25] H. Ackermann,et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. , 1999, Gastroenterology.
[26] T. Therneau,et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. , 1999, Journal of hepatology.
[27] T. Therneau,et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. , 1999, Liver.
[28] G. V. B. Henegouwen,et al. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg , 1998, Alimentary pharmacology & therapeutics.